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ABSTRACT 
Background: Combination of oral anticoagulation (OAC) and antiplatelets is used in atrial 
fibrillation (AF) patients undergoing percutaneous coronary intervention and stent (PCI-S) 
procedure, but is associated with increased bleeding when triple antithrombotic therapy (TAT) is 
used.  Our aim was to analyse the impact of time in therapeutic range (TTR) on outcomes, in 
patients prescribed with TAT. 
Methods: Ancillary analysis from the AFCAS registry in patients assigned to TAT. TTR was 
calculated with Rosendaal method. Outcomes were analysed according to TTR tertiles 
(T1[≤56.8%]vs.T2[56.9-93.8%]vs.T3[≥93.9%]). Major bleeding was the primary outcome. 
Results: Of 963 patients enrolled, 470(48.8%) were prescribed with TAT at discharge and qualified 
for this analysis. Median [IQR] TTR was 80.0%[45.3-100%]. After 359[341-370] days, major 
bleeding rates were progressively lower with increasing TTR tertiles 
(T1vs.T2vs.T3:10.3%vs.4.7%vs.2.3%,p=0.006).  
Kaplan-Meier analysis demonstrated a progressively lower risk for major bleeding across tertiles 
(p=0.006). Patients in the highest TTR tertile had a non-significant lower risk for major adverse 
coronary and cerebrovascular events (MACCE)(Log-Rank: 4.905, p=0.086). 
Cox regression analysis showed that T2 and T3 were inversely associated with major bleeding 
(hazard ratio[HR]:0.39,p=0.050 and HR:0.21,p=0.005). Continuous TTR was inversely associated 
with major bleeding (HR:0.98,p<0.001). For MACCE, adjusted Cox analysis found a non-significant 
lower risk for T3 (HR:0.64,p=0.128).     
Conclusions: In AF patients undergoing PCI-S prescribed TAT, good quality anticoagulation control 
(as reflected by TTR) was closely related to bleeding outcomes during follow-up. Despite some 
suggestive trends for an inverse relationship between TTR and MACCE, no definitive conclusions 
can be drawn, and further large studies are needed. 
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Keywords: atrial fibrillation; percutaneous coronary intervention; triple antithrombotic therapy; 
anticoagulation control; outcomes.  
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INTRODUCTION 
In patients with atrial fibrillation (AF), concomitant coronary artery disease is often present (1).   
Many uncertainties still exist about the concomitant use of antiplatelet and oral anticoagulation 
(OAC) therapy in this clinical setting, especially in AF patients undergoing percutaneous coronary 
intervention with stenting (PCI-S) (2). Indeed, a balance should be obtained between stroke 
prevention in AF (which requires OAC), stent thrombosis and recurrent cardiac ischemia (both 
requiring dual antiplatelet therapy) and serious bleeding (by combining OAC with antiplatelet 
therapy). 
 
The use of triple antithrombotic therapy (TAT), namely aspirin, any P2Y12 inhibitor (i.e. 
clopidogrel, prasugrel, ticagrelor) and OAC with a vitamin K antagonist (VKA), is associated with a 
higher risk for serious bleeding (3), despite targeting lower international normalized ratio (INR) 
values (3). An increased risk of bleeding with TAT has been documented, in hospitalized AF 
patients(4) and in those following myocardial infarction (MI) or a PCI-S (5). 
 
Major guidelines (6,7) currently recommend initial TAT, even if only for a short period of time, 
followed by a period of single antiplatelet therapy plus OAC up to 12 months after PCI-S. In 2014, 
the joint European consensus document endorsed by the Heart Rhythm Society and Asia-Pacific 
Heart Rhythm Society on the management of AF patients presenting with an acute coronary 
syndrome or undergoing PCI-S was published, which recommended evaluation of thromboembolic 
(CHA2DS2-VASc score) and bleeding (HAS-BLED score) risks, followed by consideration of 
antithrombotic strategy based on presentation (acute vs. elective) and type of stent (8).  However, 
thromboembolic and bleeding risks with VKA are closely related to quality of anticoagulation 
control, as reflected by time in therapeutic range (TTR) within an INR 2.0-3.0(9). 
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The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry was a prospective 
multicentre European registry including AF patients undergoing PCI-S. Baseline and 1 year 
outcomes from AFCAS have been previously published (10,11).  The objective of this ancillary 
study from AFCAS was to relate major adverse outcomes, primarily major bleeding, in AF patients 
prescribed TAT after a PCI-S to quality of anticoagulation control, as reflected by TTR. Secondary 
outcomes were cardiovascular/cerebrovascular events. 
 
METHODS 
The AFCAS registry was an observational, prospective, multicentre study about the clinical 
management of AF patients undergoing PCI-S. In brief, all AF patients referred for a PCI-S 
procedure were eligible to take part in the study. A 12-months follow-up observation period was 
planned in order to record all major adverse outcomes. For this study, all patients prescribed TAT 
at discharge after the PCI-S procedure with complete data about clinical characteristics, follow-up 
observation and available data about TTR throughout the study follow-up period were analysed.  
 
Thromboembolic risk was categorised according to CHA2DS2-VASc score(12). “Low risk” patients 
were defined as males with a CHA2DS2-VASc =0 or females with CHA2DS2-VASc =1; “moderate risk” 
was defined as male patients with CHA2DS2-VASc=1; and “high risk” with CHA2DS2-VASc ≥2. TTR 
was calculated according to Rosendaal interpolation method(13). INRs considered for TTR 
calculation were performed at baseline and at every subsequent follow-up visits (1 month, 3 
months, 6 months, 12 months). Baseline INR range was 2.0-3.0 in 456 out of 470 patients (97.0%), 
while 6 patients were in the lower range (INR<2.0) and 8 patients were in the higher range 
(INR>3.0). Effective anticoagulation control using VKA was defined as a TTR >70%(14).  
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To fulfil the aims of this study we performed two distinct analysis: first, we evaluated the “dose-
effect” response between progressively higher TTR tertiles and the occurrence of outcomes. 
Second, we evaluated the effect of having best quality anticoagulation control (i.e. the highest TTR 
tertile, compared to others) in relation to major adverse events. Last, we tested the relationship 
between effective anticoagulation control (i.e. TTR >70%) and major adverse events in a sensitivity 
analysis. 
 
Based on the original protocol, the principal safety outcomes were ‘major bleeding’, defined as 
intracranial, bleeding requiring blood transfusion or surgical/endoscopic treatment or leading to 
long-term disability or death, and ‘clinically relevant non-major bleeding’ (CRNMB), which was 
bleeding requiring no treatment or leading to ambulatory management with no 
surgical/endoscopic treatment. 
 
Furthermore, the principal efficacy outcome was a composite of major acute 
cardiovascular/cerebrovascular events (MACCE), including acute MI, target vessel 
revascularization, stroke/transient ischemic attack (TIA), systemic embolic event, stent thrombosis 
and cardiovascular death. Acute MI was defined according to the universal definition in use at the 
time of the study (15). Target vessel revascularization was defined as PCI-S or coronary bypass 
surgery in the previously treated vessel. Stent thrombosis was defined according to the Academic 
Research Consortium classification and included definite and probable events(16). TIA was defined 
as a focal, transient (<24 hours) neurological deficit adjudicated by a neurologist, whereas stroke 
was defined as a permanent, focal, neurological deficit adjudicated by a neurologist and confirmed 
by computed tomography/magnetic resonance imaging. Systemic embolism was defined as 
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signs/symptoms of peripheral ischemia associated or not with a positive imaging test. 
Cardiovascular death was defined as a death related to cardiac cause or stroke.  
 
Statistical Analysis 
Patients were categorized according to TTR tertiles, defined as follows: 1st Tertile (T1) <56.8%; 2nd 
Tertile (T2) 56.9-93.8%; 3rd Tertile (T3) >93.9%. Continuous variables were reported as median 
[IQR] and differences between subgroups were assessed with Kruskal-Wallis 1-way ANOVA test. 
Categorical variables, expressed as counts and percentages, were analysed by chi-squared test, 
with Bonferroni correction for evaluation of pairwise comparisons between groups. 
 
Differences in survival were analysed using the log-rank test and Kaplan-Meier analysis according 
to TTR tertiles and, additionally, comparing patients in T3 to those in the other two tertiles 
combined. In order to establish if TTR was independently associated with major bleeding and 
MACCE a Cox proportional-hazards analysis, adjusted for age, gender, AF type, CHA2DS2-VASc 
score, PCI-S clinical indication and PCI-S clinical setting for both outcomes, was performed. Two 
distinct models were performed using TTR tertiles, both comparing T1, T2 and T3 distinctly, and 
secondly, comparing T3 to the other two tertiles.  Furthermore, we constructed a third model 
using TTR as a continuous variable. A two-sided p value <0.05 was considered statistically 
significant. In the additional sensitivity analysis, a similar analytical approach was followed using 
the log-rank test and Kaplan-Meier analysis for TTR >70%, followed by Cox proportional-hazards 
analysis using the same adjustments. All analyses were performed using SPSS v. 22.0 (IBM, NY, 
USA).
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RESULTS 
Of the 963 patients originally enrolled in the AFCAS study, 470 (48.8%) patients were eligible for 
this ancillary analysis. These patients subdivided according to TTR tertiles were as follows: 145 
(30.8%) in T1; 149 (31.7%) in T2; 176 (37.4%) in T3. As expected, median TTR values across tertiles 
progressively increased [Figure 1].  
 
Baseline characteristics according to TTR tertiles are shown in Table 1. Patients in the three TTR 
tertiles did not show significant differences in the baseline characteristics except for the 
prevalence of diabetes mellitus, higher in T1 compared to T2 and T3 (p=0.034). Previous 
gastrointestinal bleeding was more prevalent in T2 patients (p=0.030). Femoral vascular access 
was progressively less prevalent from patients in T1 to T3 (p=0.006). 
 
Follow-Up and Survival Analysis 
After a median [IQR] follow-up of 359 [341-370] days, a total of 26 (5.5%) major bleeding and 58 
(12.3%) CRNMB events occurred, whilst 82 (17.4%) MACCE were recorded. At 12-months follow-
up, 52 (11.1%) patients were still on triple therapy; no significant differences were found between 
the three tertiles (data not shown). 
 
Outcomes according to TTR tertiles are shown in Table 2. Major bleeding rate progressively 
decreased from T1 to T3 patients (p=0.006). For MACCE, patients in T2 reported the highest event 
rate (21.5%), while patients in T3 reported the lowest rate of MACCE (11.9%); this difference was 
not statistically significant (p=0.066). 
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Survival analysis found a progressive decrease in cumulative risk for major bleeding across the 
three TTR tertiles (Log-Rank: 10.320, p=0.006) [Figure 2, Left Panel].  A non-significant trend for 
progressively lower MACCE risk was found [Figure 2 Right Panel] (Log-Rank: 4.905, p=0.086).  
 
Comparing patients in the highest TTR tertile (T3) to those in the other two (T1-T2), a lower risk for 
major bleeding was confirmed in T3 [Figure S1, Left Panel; Log-Rank: 5.770, p=0.016). A lower risk 
for MACCE was found in T3 compared to T1-T2 (Log-Rank: 4.420, p=0.036) [Figure S1, Right Panel].   
 
A multivariable Cox regression analysis (Table 3) showed that both T2 and T3 tertiles were 
inversely associated with major bleeding (p=0.050 and p=0.005, respectively). Model 2 confirmed 
that the best anticoagulation control (T3) had the lowest risk for major bleeding (p=0.027). The 
third Cox model, with TTR as a continuous variable, showed that TTR was inversely associated with 
major bleeding (p<0.001).   
 
For MACCE, the Model 1 adjusted Cox analysis found a non-significant lower risk for patients in T3 
(p=0.128). In Model 2, obtaining the best anticoagulation control was inversely associated with 
MACCE events occurrence (T3 vs. T1/T2, p=0.033). The final model with continuous TTR showed a 
non-significant trend for an inverse relationship with MACCE (p=0.069). 
 
Sensitivity Analysis 
We performed a sensitivity analysis taking the TTR >70% cut-off as reference (Supplementary 
Materials). Major bleeding was significantly lower in patients with TTR >70% compared to those 
with TTR 70% (2.2% vs. 10.0%, respectively; p<0.001).  There was a non-significant trend for 
lower MACCE events (14.1% vs. 20.5%, respectively; p=0.065) (Table S1). Kaplan-Meier curves 
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[Figures S2-S3] confirmed a significantly lower risk for major bleeding with TTR >70% [Figure S2]. 
Cox regression analysis (Table S2) found that TTR >70% was independently associated with a lower 
risk for major bleeding (p<0.001). 
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DISCUSSION 
In our study of AF patients undergoing a PCI-S procedure prescribed with TAT, our principal finding 
is that good anticoagulation control in VKA users, as reflected by a high TTR, was inversely 
associated with both major bleeding and MACCE. Specifically, we show a progressive stepwise risk 
reduction for major bleeding when going from lowest to higher TTR tertiles. Similarly, patients 
with the best anticoagulation control had the lowest risk of major bleeding compared to all the 
other patients. As far as we are aware, we provide the first data relating major bleeding to TTR in 
the setting of PCI-S and AF. 
 
Several studies have shown that AF patients prescribed TAT have a higher risk for major bleeding. 
In a large cohort derived from the Danish nationwide cohort study, patients on TAT had almost 
four-fold higher risk for the composite of major fatal and non-fatal bleeding (hazard ratio [HR]: 
3.70, 95% confidence interval [CI]: 2.89-4.76), with no reduction in stroke occurrence (HR: 1.45, 
95% CI: 0.84-2.52)(4). More recently, a the Get-With-The-Guidelines programme reported an 
increased risk for bleeding-related hospitalizations for AF patients prescribed TAT, with a 2-fold 
increased risk of intracranial haemorrhage-related hospitalizations (HR: 2.04, 95% CI: 1.25-
3.34)(17). No difference was found in efficacy outcomes when comparing TAT patients with those 
prescribed dual antiplatelet therapy (17). 
 
Other registry evidence has confirmed a higher risk of bleeding associated with TAT, with up to a 
2-fold higher risk for any bleeding (HR: 2.08, 95% CI: 1.64-2.65), with a higher short-term risk, as 
well as a significant association with fatal bleeding at 30 days after discharge (HR: 1.85, 95% CI: 
1.27-2.70)(5); however, there was also a significant reduction in ischemic stroke (HR: 0.67, 95% CI: 
0.46-0.98), all-cause death (HR: 0.61, 95% CI: 0.47-0.77) and the composite outcomes for AF 
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patients treated with TAT(5). Similar data have been reported in elderly patients, with a 5-fold 
increased risk for major bleeding, with concomitant reductions of thromboembolic events and all-
cause death (18).  However, all these registry studies do not provide data in relation to TTR.  
In this context, our data show how the risk of bleeding during TAT is dependent on the quality of 
anticoagulation control, as reflected by the TTR. 
 
Despite being inconclusive for MACCE, our data are suggestive of the importance of the quality of 
anticoagulation control in obtaining improved outcomes(19–21). Our three tertiles were mostly 
comparable in clinical characteristics, additional residual confounders could have influenced the 
increased rate of MACCE for patients in T2, beyond the quality of anticoagulation control. 
Nevertheless, patients in T3 had the lowest rate of MACCE events suggesting that better control of 
TTR may lower the risk.  Larger prospective studies would be needed to confirm these trends. 
 
Several published studies have reported how TTR is a strong predictor of both thromboembolic-
related and bleeding-related outcomes, independent from body weight(22), renal function(23) 
and gender(24). Moreover, the importance of anticoagulation control in properly evaluating 
potential bleeding risk has been recently  shown (25,26). In a large systematic review, Wan et al 
clearly show an inverse linear association between TTR and outcomes, both bleeding and 
thromboembolic (9). More recently, a large observational study confirmed the inverse relationship 
between TTR and adverse outcomes(27). 
 
The joint European consensus document recommends evaluation of the balance between 
thromboembolic and bleeding risks, then minimizing the period of TAT treatment to 4 weeks in 
patients with a high risk of bleeding (HAS-BLED ≥3), followed by 12 months of single antiplatelet 
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therapy with clopidogrel and OAC, either with a VKA (e.g. warfarin) or non-vitamin K antagonist 
oral anticoagulant (NOAC)(8).  For VKA therapy, a narrower therapeutic range is recommended 
(INR 2.0-2.5) and for NOACs, the lower approved dose for stroke prevention in AF should be used 
(8). In the WOEST trial, clopidogrel plus warfarin was associated with a reduced risk of any 
bleeding (Iargely driven by reduction in minor bleeds) compared to TAT without any increase in 
thrombotic events (28). Despite that, WOEST did not provide any data in relation to TTR. Our 
results substantiate the recommendations in the European consensus document on maintaining 
optimal anticoagulation control while taking VKA.  
 
Recently, results from the “Open-Label, Randomized, Controlled, Multicenter Study Exploring Two 
Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment 
Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention” 
(PIONEER AF-PCI)(29) showed that the two arms with different rivaroxaban doses, 15 mg and 2.5 
mg, resulted in a significantly lower risk of any significant bleeding (TIMI major or TIMI minor 
bleeding or bleeding requiring medical attention) compared to VKA therapy (HR: 0.59, 95% CI: 
0.47-0.76 and HR: 0.63, 95% CI: 0.50-0.80 respectively for rivaroxaban 15 mg and rivaroxaban 
2.5)(30). Despite a significant reduction of recurrent hospitalization (particularly those related to 
bleeding and cardiovascular reasons)(31), this study did not show significant reduction in all major 
adverse cardiovascular events, due to limited power(30). The overall TTR recorded for the VKA 
arm was 65%, but the use of NOACs in this setting seems encouraging. Several ongoing 
randomised clinical trials would provide additional evidence (32). 
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Limitations 
The main limitation of this study is the post-hoc subgroup retrospective design, which was not 
powered to detect differences in the specified subgroups, warranting further confirmation from 
adequately powered prospective studies. Even if the groups considered were comparable 
according to the baseline characteristics, the presence of additional confounders cannot be 
completely excluded and fully accounted for. Also, the limited number of patients still on TAT at 1 
year follow-up would represents another limitation.  Nonetheless, we still show important 
associations particularly for bleeding events, in relation to tertiles of TTR.  Some suggestive trends 
for an inverse relationship between TTR and MACCE, but our data do not allow us to draw definite 
conclusions, requiring further adequately powered studies to confirm this aspect.   
 
In conclusion, in AF patients undergoing a PCI-S prescribed TAT, good quality anticoagulation 
control (as reflected by TTR) was closely related to better bleeding outcomes during follow-up. 
Despite some suggestive trends for an inverse relationship between TTR and MACCE, no definitive 
conclusions can be drawn, and further large studies are needed.  
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FIGURES LEGENDS 
Figure 1: TTR values distribution according to tertiles. 
Legend: TTR= time in therapeutic range. Dashed line and error bars= Median [IQR]. 
 
Figure 2: Kaplan-Meier curves for major adverse events according to TTR tertiles. 
Legend: MACCE= major adverse cardiac/cerebrovascular events.  
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Table 1: Baseline characteristics according to TTR tertiles 
 1st Tertile 
n= 145 
2nd Tertile 
n= 149 
3rd Tertile 
n= 176 
p 
Age, (years) median [IQR] 74 [68-78] 74 [69-79] 74 [29-79] 0.760 
Female, n (%) 42 (29.0) 42 (28.2) 49 (27.8) 0.975 
BMI, (kg/m2) median [IQR] 28 [25-32] 28 [25-31] 28 [25-30] 0.606 
CrCl, (ml/min) median [IQR] 403 69.6  
[54.1-94.4] 
68.0 
[50.3-89.1] 
71.9 
[57.4-94.8] 
0.333 
TTR, (%) median [IQR] 28.1  
[4.1-42.7] 
76.0 
[63.5-83.4] 
100.0  
[98.8-100..0] 
<0.001 
Prescribed TAT Duration, n (%)    0.687 
0-3 months 68 (46.9) 79 (53.0) 90 (51.1)  
3-6 months 36 (24.8) 29 (19.5) 43 (24.4)  
≥6 months 41 (28.3) 41 (27.5) 43 (24.4)  
AF Type, n (%) 464 
Paroxysmal 
Persistent 
Permanent 
 
42 (29.2) 
15 (10.4) 
87 (60.4) 
 
43 (29.7) 
13 (9.0) 
89 (61.4) 
 
46 (26.1) 
18 (10.2) 
111 (63.4) 
0.951 
Hypertension, n (%) 115 (79.3) 121 (81.2) 142 (80.7) 0.914 
Hypercholesterolemia, n (%) 95 (65.5) 106 (71.1) 112 (63.6) 0.341 
Diabetes Mellitus, n (%) 59 (40.7) 44 (29.5) 49 (27.8) 0.034 
Smoking Habit, n (%) 13 (9.0) 10 (6.7) 15 (8.5) 0.750 
Coronary Artery Disease, n (%) 47 (32.4) 49 (32.9) 69 (39.2) 0.353 
Previous MI, n (%) 36 (24.8) 35 (23.5) 45 (25.6) 0.909 
Previous PCI, n (%) 18 (12.4) 17 (11.4) 28 (15.9) 0.453 
Previous CABG, n (%) 25 (17.2) 32 (21.5) 23 (13.1) 0.132 
Chronic Heart Failure, n (%) 27 (18.6) 28 (18.8) 23 (13.1) 0.282 
Ejection Fraction, (%) median [IQR] 50 [40-60] 52 [40-60] 50 [40-60] 0.968 
Previous Stroke/TIA, n (%) 28 (19.3) 27 (18.1) 36 (20.5) 0.869 
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Previous Bleeding, n (%) 2 (1.4) 10 (6.7) 6 (3.4) 0.055 
Previous Cerebral Bleeding, n (%) 1 (0.7) 2 (1.3) 2 (1.1) 0.856 
Previous GI Bleeding, n (%) 1 (0.7) 7 (4.7) 2 (1.1) 0.030 
Previous GU Bleeding, n (%) 0 (0.0) 1 (0.7) 1 (0.6) 0.632 
CHA2DS2-VASc, median [IQR] 3 [3-5] 3[3-5] 4 [2-4] 0.718 
Thromboembolic Risk, n (%) 
Low Risk 
Moderate Risk 
High Risk 
 
0 (0.0) 
8 (5.5) 
137 (94.5) 
 
2 (1.3) 
15 (10.1) 
132 (88.6) 
 
3 (1.7) 
15 (8.5) 
158 (89.8) 
0.331 
PCI Clinical Indication, n (%) 
Stable Angina 
NSTE-ACS 
STEMI 
Other 
 
61 (42.1) 
59 (40.7) 
19 (13.1) 
6 (4.1) 
 
70 (47.0) 
54 (36.2) 
20 (13.4) 
5 (3.4) 
 
80 (45.5) 
66 (37.5) 
20 (11.4) 
10(5.7) 
0.903 
PCI Clinical Setting, n (%) 
Emergency 
Urgency 
Elective 
 
70 (48.3) 
56 (38.6) 
19 (13.1) 
 
73(49.0) 
53 (35.6) 
23 (15.4) 
 
96 (54.5) 
64 (36.4) 
16 (9.1) 
0.449 
N Diseased Vessels, median [IQR] 2 [1-3] 2 [1-3] 2 [1-3] 0.460 
N Treated Vessels, median [IQR] 1 [1-1] 1 [1-1] 1 [1-1] 0.717 
Lesion Type, n (%) 444 
A 
B1/B2 
C 
 
24 (18.2) 
83 (62.9) 
25 (18.9) 
 
21 (15.3) 
81 (59.1) 
35 (25.5) 
 
22 (12.6) 
118 (67.4) 
35 (20.0) 
0.398 
Vascular Access, n (%) 
Radial 
Femoral 
Other 
 
36 (24.8) 
107 (73.8) 
2 (1.4) 
 
53 (35.6) 
96 (64.4) 
0 
 
77 (43.8) 
98 (55.7) 
1 (0.6) 
0.006 
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Complete Revascularization, n (%) 463 65 (46.8) 65 (43.6) 86 (49.1) 0.611 
Stent Type, n (%) 464 
DES 
Bioactive 
BMS 
Other 
 
36 (25.0) 
25 (17.4) 
78 (54.2) 
5 (3.5) 
 
38 (25.9) 
37 (25.2) 
66 (44.9) 
6 (4.1) 
 
41 (23.7) 
37 (21.4) 
82(47.4) 
13 (7.5) 
0.361 
Legend: ACS= acute coronary syndrome; AF= atrial fibrillation; BMS= bare metal stent; CABG= 
coronary artery by-pass graft; DES= drug eluting stent; GI= gastro-intestinal; GU= genital-urinary; 
IQR= interquartile range; MI= myocardial infarction; NSTE= non ST elevation; PCI= percutaneous 
coronary intervention; STEMI= ST elevation myocardial infarction; TIA= transient ischemic attack.  
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Table 2: Major adverse events at follow-up according to TTR tertiles 
 1st Tertile 
n= 145 
2nd Tertile 
n= 149 
3rd Tertile 
n= 176 
p 
Major Bleeding, n (%) 15 (10.3) 7 (4.7) 4 (2.3) 0.006 
CRNMB, n (%) 21 (14.5) 19 (12.8) 18 (10.2) 0.505 
MACCE, n (%) 26 (17.9) 32 (21.5) 21 (11.9) 0.066 
Legend: CRNMB= clinical relevant non-major bleeding; MACCE= major adverse 
cardiac/cerebrovascular events; MI= myocardial infarction; TIA= transient ischemic attack. 
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Table 3: Cox regression analysis for major adverse events* 
 Hazard Ratio 95% CI p 
Major Bleeding    
Model 1 
TTR 1st Tertile 
TTR 2nd Tertile 
TTR 3rd Tertile 
 
Ref. 
0.39 
0.21 
 
Ref. 
0.15-1.00 
0.07-0.63 
 
Ref. 
0.050 
0.005 
Model 2 
TTR 1st/2nd Tertiles 
TTR 3rd Tertile 
 
Ref. 
0.30 
 
Ref. 
0.10-0.87 
 
Ref. 
0.027 
Model 3 
TTR (%) 
 
0.98 
 
0.97-0.99 
 
<0.001 
MACCE    
Model 1 
TTR 1st Tertile 
TTR 2nd Tertile 
TTR 3rd Tertile 
 
Ref. 
1.21 
0.64 
 
Ref. 
0.72-2.04 
0.36-1.14 
 
Ref. 
0.474 
0.128 
Model 2 
TTR 1st/2nd Tertiles 
TTR 3rd Tertile 
 
Ref. 
0.58 
 
Ref. 
0.35-0.96 
 
Ref. 
0.033 
Model 3 
TTR (%) 
 
0.99 
 
0.99-1.00 
 
0.069 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 28 
Legend: *adjusted for age, gender, AF type, CHA2DS2-VASc, PCI-S clinical indication, PCI-S clinical 
setting. AF= atrial fibrillation; MACCE= major adverse cardiac/cerebrovascular events; PCI= 
percutaneous coronary intervention; TTR= time in therapeutic range. 
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Figure 1 
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Figure 2 
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HIGHLIGHTS 
 Atrial fibrillation (AF) is associated with significant coronary artery disease 
 In AF patients undergoing stenting, triple antithrombotic therapy (TAT) is often used 
 Use of TAT in AF patients is associated with a higher risk of bleeding 
 Time in therapeutic range (TTR) is associated with better bleeding outcomes 
 High TTR during TAT in AF after stenting is associated to improved bleeding outcomes 
